Literature DB >> 22512621

Familial amyloidotic polyneuropathy type IV--gelsolin amyloidosis.

Tiia Pihlamaa1, Sinikka Suominen, Sari Kiuru-Enari.   

Abstract

Familial amyloidotic polyneuropathy type IV, or Gelsolin amyloidosis (GA), is a rare condition caused by G654A or G654T mutation in gelsolin gene at 9q32-34. Gelsolin seems essential in many processes, including inflammation, cell motility, neural recovery, apoptosis and even carcinogenesis. So far reported from many European countries, USA, Japan, Iran and Brazil, GA is probably still underdiagnosed. The typical diagnostic triad includes corneal lattice dystrophy, progressive bilateral facial paralysis and cutis laxa. Patients present with progressive cranial and peripheral neuropathy, eye symptoms, usually mild proteinuria, and cardiac conductive disturbances with age. Central nervous system symptoms are rare. Gelsolin amyloid collection in tissues is widespread. To date, treatment is symptomatic. Regular check-ups with ophthalmologist are recommended. Plastic surgery relieves the functional symptoms caused by facial paralysis and loose, hanging facial skin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512621     DOI: 10.3109/13506129.2012.674076

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  3 in total

1.  Regulatory role of the second gelsolin-like domain of Caenorhabditis elegans gelsolin-like protein 1 (GSNL-1) in its calcium-dependent conformation and actin-regulatory activities.

Authors:  Zhongmei Liu; Shoichiro Ono
Journal:  Cytoskeleton (Hoboken)       Date:  2013-03-21

Review 2.  Clinical and mechanism advances of neuronal intranuclear inclusion disease.

Authors:  Yueqi Liu; Hao Li; Xuan Liu; Bin Wang; Hao Yang; Bo Wan; Miao Sun; Xingshun Xu
Journal:  Front Aging Neurosci       Date:  2022-09-13       Impact factor: 5.702

3.  On the role of aggregation prone regions in protein evolution, stability, and enzymatic catalysis: insights from diverse analyses.

Authors:  Patrick M Buck; Sandeep Kumar; Satish K Singh
Journal:  PLoS Comput Biol       Date:  2013-10-17       Impact factor: 4.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.